These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 29071588)

  • 1. A Retrospective Medical Record Review of Utilization Patterns and Medical Resource Use Associated with Repository Corticotropin Injection among Patients with Rheumatologic Diseases in the United States.
    Nelson WW; Philbin MJ; Gallagher JR; Heap K; Carroll S; Wan GJ
    Rheumatol Ther; 2017 Dec; 4(2):465-474. PubMed ID: 29071588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Economic Evaluation of Repository Corticotropin Injection: A Narrative Literature Review of Treatment Efficacy and Healthcare Resource Utilization for Seven Key Indications.
    Philbin M; Niewoehner J; Wan GJ
    Adv Ther; 2017 Aug; 34(8):1775-1790. PubMed ID: 28660550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Dermatomyositis/Polymyositis.
    Ho-Mahler N; Turner B; Eaddy M; Hanke ML; Nelson WW
    Open Access Rheumatol; 2020; 12():21-28. PubMed ID: 32110122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Demographics, treatment patterns, and healthcare utilization and cost of repository corticotropin injection in patients with systemic lupus erythematosus or rheumatoid arthritis.
    Wu B; Deshpande G; Gu T; Popelar B; Philbin M; Wan GJ
    J Med Econ; 2017 Nov; 20(11):1170-1177. PubMed ID: 28760047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pain and Fatigue Improvements in Patients Treated with Repository Corticotropin Injection Across Five Indications: A Narrative Review.
    Girman C; Panaccio MP; Hayes K; Niewoehner J; Wan GJ
    Adv Ther; 2022 Jul; 39(7):3072-3087. PubMed ID: 35635646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical resource utilization in dermatomyositis/polymyositis patients treated with repository corticotropin injection, intravenous immunoglobulin, and/or rituximab.
    Knight T; Bond TC; Popelar B; Wang L; Niewoehner JW; Anastassopoulos K; Philbin M
    Clinicoecon Outcomes Res; 2017; 9():271-279. PubMed ID: 28553129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acthar Gel (RCI): A Narrative Literature Review of Clinical and Economic Evidence.
    Wan GJ; Niewoehner J; Hayes K
    Clinicoecon Outcomes Res; 2023; 15():499-512. PubMed ID: 37397803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Repository Corticotropin Injection on Medication Use in Patients With Rheumatologic Conditions: A Claims Data Study.
    Myung G; Nelson WW; McMahon MA
    J Pharm Technol; 2017 Aug; 33(4):151-155. PubMed ID: 34861677
    [No Abstract]   [Full Text] [Related]  

  • 9. Real-World Treatment Patterns and Outcomes from an Electronic Medical Records Database for Patients with Rheumatoid Arthritis Treated with Repository Corticotropin Injection.
    Hayes K; Panaccio MP; Houston P; Niewoehner J; Fahim M; Wan GJ; Dhillon B
    Open Access Rheumatol; 2021; 13():315-323. PubMed ID: 34703332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective Medical Record Review to Describe Use of Repository Corticotropin Injection Among Patients with Uveitis in the United States.
    Nelson WW; Lima AF; Kranyak J; Opong-Owusu B; Ciepielewska G; Gallagher JR; Heap K; Carroll S
    J Ocul Pharmacol Ther; 2019 Apr; 35(3):182-188. PubMed ID: 30676837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world treatment patterns for repository corticotropin injection in patients with rheumatoid arthritis.
    Busch H; Wan GJ; Niewoehner J; Houston P; Su Y; Clinton C; Panaccio MP
    Drugs Context; 2022; 11():. PubMed ID: 35382109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repository corticotropin injection in patients with advanced symptomatic sarcoidosis: retrospective analysis of medical records.
    Chopra I; Qin Y; Kranyak J; Gallagher JR; Heap K; Carroll S; Wan GJ
    Ther Adv Respir Dis; 2019; 13():1753466619888127. PubMed ID: 31722624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient Characteristics and Indicators of Treatment Initiation with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis: A Claims Database Analysis.
    Hayes K; Panaccio MP; Goel N; Fahim M
    Rheumatol Ther; 2021 Mar; 8(1):327-346. PubMed ID: 33400194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medication Utilization Patterns 90 Days Before Initiation of Treatment with Repository Corticotropin Injection in Patients with Infantile Spasms.
    Gold LS; Nazareth TA; Yu TC; Fry KR; Mahler NH; Rava A; Waltrip Ii RW; Hansen RN
    Pediatric Health Med Ther; 2019; 10():195-207. PubMed ID: 32099512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Narrative Review of Repository Corticotropin Injection for the Treatment of Systemic Lupus Erythematosus.
    Askanase AD; Furie RA
    Adv Ther; 2022 Jul; 39(7):3088-3103. PubMed ID: 35641860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar
    Askanase AD; Wan GJ; Panaccio MP; Zhao E; Zhu J; Bilyk R; Furie RA
    Rheumatol Ther; 2021 Mar; 8(1):573-584. PubMed ID: 33687687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post Hoc Biomarker Analyses from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus.
    Askanase AD; Wright D; Zhao E; Zhu J; Bilyk R; Furie RA
    Rheumatol Ther; 2021 Dec; 8(4):1871-1886. PubMed ID: 34478124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
    Askanase AD; Zhao E; Zhu J; Bilyk R; Furie RA
    Rheumatol Ther; 2020 Dec; 7(4):893-908. PubMed ID: 32996096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consequences of Insurance Denials Among U.S. Patients Prescribed Repository Corticotropin Injection for Acute Exacerbations of Multiple Sclerosis.
    Rice JB; Panaccio MP; White A; Simes M; Billmyer E; Downes N; Niewoehner J; Wan GJ
    Neurol Ther; 2021 Jun; 10(1):149-167. PubMed ID: 33170434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consequences of insurance denials among U.S. patients prescribed repository corticotropin injection (Acthar Gel) for nephrotic syndrome.
    Rice JB; Panaccio MP; White A; Simes M; Billmyer E; Downes N; Niewoehner J; Wan GJ
    Curr Med Res Opin; 2021 Mar; 37(3):431-441. PubMed ID: 33411573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.